Boehringer's puzzling rare kidney disease data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 28 January, 2026

Finally unify brand and field strategy, execution, and measurement. PharmaForceIQ acquires Aktana to create pharma’s most advanced customer engagement platform. sponsored by PharmaForceIQ

presented by Da­ta as a su­per­pow­er: How In­te­grat­ed Da­ta De­liv­ery trans­forms clin­i­cal tri­al time­lines

news Lilly partners with startup developing recombinase-based gene editing Exclusive: Cellares raises $257M to fund global expansion as it eyes 2027 IPO Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data Updated: CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Vice President, Investor Relations & Communications C4 Therapeutics Watertown, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. Exclusive: In major test for longevity field, FDA greenlights study on a 'near total reset' of cells 2. Cardiff's shares dive after muddled Phase 2 data drop, executive departures 3. Hospitals could earn more for buying US-made drugs, CMS proposes 4. Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcere 5. Updated: Roche’s obesity shot posts decent weight loss in mid-stage test, heads to Phase 3 6. TRexBio gets another $50M to bring more Treg candidates into the clinic 7. FDA lifts hold on one of two Phase 3 gene editing studies by Intellia 8. News Briefing AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal 9. UK and US biotech investor Epidarex raises $145M for fourth fund 10. Insilico’s latest deal is a $120M cardiometabolic drug discovery pact 11. Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows 12. Why UK biotech keeps selling itself to America

.